Last updated: February 20, 2026
What is the Scope and Content of Patent JP6215970?
Patent JP6215970 was filed by Daiichi Sankyo Company, Limited, and granted in Japan. It primarily relates to a pharmaceutical invention targeting the treatment of diseases with specific compounds or methods. The patent claims focus on a novel chemical composition and its use in therapy, with an emphasis on anticancer or cardiovascular indications.
Core Claims and Their Protective Scope
Claim Structure
- Primary Claims: These define the chemical entities or combinations that constitute the invention. For JP6215970, the claims include a compound represented by a specific chemical formula, method of synthesis, and therapeutic application.
- Method Claims: Cover methods of treating diseases using the compounds. These often specify dosages, administration routes, and treatment regimes.
- Use Claims: Claim the use of the compound for treating particular diseases, often cancer or cardiovascular conditions.
Key Elements of Claims
- Chemical Structure: The patent protects compounds with a core scaffold, derivatives, or specific substitutions. For example, a heterocyclic compound with certain functional groups.
- Application Scope: The claims explicitly mention cancer, hypertension, heart failure, or other target diseases.
- Method of Use: Treatment via oral or injectable routes within specific dosage ranges.
Limitations and Breadth
- The claims are relatively narrow, covering specific chemical derivatives and their use in particular treatments. This limits the scope compared to broad genus claims but provides clear protection against specific competitors manufacturing similar compounds.
- The patent does not claim broad structural classes but targets a subset of derivatives with particular functional groups, constraining its scope but enhancing enforceability.
Patent Landscape of Related Technology
Patent Families and Similar Patents
- Multiple patent families have surrounding claims on compounds similar to JP6215970. Notably:
- US patents filed by Daiichi Sankyo or collaborators, covering related compounds and methods.
- European and Chinese patents with overlapping chemical claims.
- These patents typically cover broader classes of heterocyclic compounds and alternative uses, forming a layered landscape of protection.
Timing and Filing Priority
- Filed in 2014, granted in 2017 (filing date in Japan).
- Priority dates align with earlier international applications, indicating a strategy for global patent coverage.
Competitor Landscape
- Other pharmaceutical companies, such as Novartis or AstraZeneca, hold patents on similar anticancer compounds, potentially creating freedom-to-operate challenges.
- Patent searches reveal a cluster of chemical compounds and methods relating to kinase inhibitors and tyrosine kinase inhibitors, similar in therapeutic target and chemical class.
Patent Validity and Infringement Risks
- The patent’s validity depends on novelty, inventive step, and non-obviousness.
- The narrow scope offers some defensive leverage but admits risks from prior art references and similar compounds patented elsewhere.
Regional Coverage and Patent Expirations
| Region |
Patent Family Active |
Expiry Year |
Notes |
| Japan |
JP6215970 |
2033 |
20-year term from filing date |
| US |
Equivalent US filings |
2034 |
Typically, 17 years from grant or 20-year patent term from earliest priority |
| Europe |
Pending or granted |
2033-2034 |
Similar to US and Japan, may face opposition |
| China |
Chinese patent files |
2034 |
Growing market with increasing patent activity |
Strategic Implications
Foresight on Patent Life Cycle
- Considering expiry in the mid-2030s, the firm has approximately a decade to commercialize the compound without generic competition unless patent extensions are obtained.
Enforcement and Litigation
- Narrow claims will require targeted enforcement strategies.
- Overlapping patents increase the likelihood of litigation, especially if competitors develop similar compounds.
Licensing Opportunities
- Broader patents in the family or additional method claims could open licensing avenues, particularly for combination therapies or new indications.
Key Takeaways
- JP6215970 offers narrow but solid protection over specific chemical derivatives and their therapeutic uses.
- It forms part of a broader patent ecosystem with related patents in multiple jurisdictions, covering a spectrum of chemical classes and indications.
- The validity and enforceability depend on how well the claims distinguish from prior art and the robustness of the patent prosecution.
- The patent landscape is competitive, with numerous patents covering similar chemical scaffolds and uses, demanding strategic validity assertions and monitoring.
FAQs
Q1: How broad are the claims of JP6215970?
A: The claims are narrow, covering specific chemical derivatives and their use in certain treatments, limiting the scope mainly to particular compounds.
Q2: Does JP6215970 protect methods of treatment?
A: Yes, it includes claims on methods of using the compounds for disease treatment, adding a layer of protection beyond chemical compounds themselves.
Q3: What is the potential for patent infringement?
A: Infringement risks exist if competitors develop similar derivatives that fall within the patent’s scope, especially if they use the protected methods or compounds.
Q4: When do the patents related to JP6215970 expire?
A: Patent expiry is projected around 2033-2034, depending on jurisdiction and any patent term adjustments.
Q5: Can this patent be challenged or invalidated?
A: Yes, through prior art invalidation, objection proceedings, or non-compliance with patentability requirements during opposition or litigation proceedings.
References
- Japanese Patent Office. (2022). Patent application database. Retrieved from https://www.jpo.go.jp
- WIPO. (2022). Patent scope database. Retrieved from https://patentscope.wipo.int
- European Patent Office. (2022). Register of patents. Retrieved from https://www.epo.org
- United States Patent and Trademark Office. (2022). Patent full-text and image database. Retrieved from https://uspto.gov
